Delivery Order SPE2DB22D3016-SPE2DB26FAAQ3
- Not listed
- The Defense Logistics Agency (DLA) awarded a $13,171.30 delivery order to AmerisourceBergen Drug Corp for 4,568,832,740 units of Actemra 400 mg/20 mL vials on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, non-set-aside contract with place of performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued...
- The Defense Logistics Agency awarded a delivery order valued at $3,386.42 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra 400 mg/20 ml vials. This firm fixed-price delivery order is scheduled for completion by September 2, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 14, 2025, for the supply of Actemra 400 mg/20 mL vials with a ceiling value of $16,140.74. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and maintains an ultimate completion date of October 15, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This is a firm fixed price delivery order with a completion date of September 2, 2025, with no set-aside designation applied. The contract represents a competitive award under DLA's broader pharmaceutical supply framework, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a $15,029.42 delivery order to AmerisourceBergen Drug Corp for Actemra 400 mg/20 ml vials on June 5, 2025, with an ultimate completion date of June 6, 2025. This non-set-aside, firm fixed price contract represents a single delivery order for a pharmaceutical product to be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $5,284.97 to AmerisourceBergen Drug Corp for the supply of Actemra 400 mg/20 ml vials. The contract, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, utilizes firm fixed price pricing with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $16,453.58. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and no set-aside designation was used in the award. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,647.70 to AmerisourceBergen Drug Corp for Actemra 200 mg/10 ml vials on September 18, 2025, with completion targeted for September 19, 2025. This firm fixed-price delivery order utilizes no set-aside designation and represents a competitive award to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The contract calls for delivery of the specified pharmaceutical product to the company's place of...
- The Defense Logistics Agency awarded a $3,729.39 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 200 mg/10 mL vials. The contract, which is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). This award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a $20,188.75 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Actemra 400 mg/20 ml vials. This is a firm fixed price, non-set-aside contract with a completion date of September 22, 2025, and performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX),...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FAAQ3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,648.95 to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Actemra 400 mg/20 mL vials. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of October 28, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs and the Defense Health Agency. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated significant capability in fulfilling federal medical supply requirements through open competition and maintains a substantial portfolio of delivery orders across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 10/27/25 |